文献速递炎症性肠病肝病

硫唑嘌呤类药物和肿瘤坏死因子拮抗剂对炎症性肠病患者原发性硬化性胆管炎结局的影响

Impact of thiopurines and tumour necrosis factor antagonists on primary sclerosing cholangitis outcomes in patients with inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2022-07-04

在法国全国队列中纳入1929例原发性硬化性胆管炎(PSC)合并炎症性肠病(IBD)患者,随访2009年1月1日至2018年12月31日,采用边际结构Cox模型分析。与未暴露者相比,暴露于硫唑嘌呤类药物或抗TNF药物者胆道癌和肝移植风险均无增加。

要点

  • 硫唑嘌呤类药物暴露者胆道癌风险无增加(HR 1.05,95%CI 0.39-2.82)。
  • 抗TNF药物暴露者胆道癌风险无增加(HR 0.59,95%CI 0.13-2.80)。
  • 硫唑嘌呤类药物或抗TNF药物暴露者肝移植风险均无增加。

核心结论

  • PSC合并IBD患者暴露于硫唑嘌呤类药物或抗TNF药物,胆道癌或肝移植风险未增加。

研究设计与样本

  • 法国全国性队列研究,基于法国国家医疗保险数据库,纳入18岁及以上PSC合并IBD患者,随访2009年1月1日至2018年12月31日,共1929例。
  • 采用边际结构Cox比例风险模型评估硫唑嘌呤类药物和抗TNF暴露与胆道癌及肝移植风险的关联,校正基线人口学和合并症、时变药物及PSC活动度。

主要发现

  • 1929例患者中发生37例胆道癌和83例肝移植。
  • 与未暴露于硫唑嘌呤类药物或抗TNF药物者相比,硫唑嘌呤类药物暴露者胆道癌风险无增加(HR 1.05;95%CI 0.39-2.82),抗TNF药物暴露者胆道癌风险无增加(HR 0.59;95%CI 0.13-2.80)。
  • 与未暴露于硫唑嘌呤类药物或抗TNF药物者相比,硫唑嘌呤类药物暴露者肝移植风险无增加(HR 0.67;95%CI 0.30-1.48),抗TNF药物暴露者肝移植风险无增加(HR 0.68;95%CI 0.22-2.09)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) are at risk of biliary tract cancer and liver damage (possibly leading to liver transplantation), and are often treated for IBD with thiopurines and/or tumour necrosis factor antagonists (anti-TNF) on a long-term basis. AIMS: To assess the risk of biliary tract cancer and liver transplantation in patients exposed to thiopurines and/or anti TNF agents in a French nationwide cohort. METHODS: We performed a population-based study of patients aged 18 years or older with PSC and IBD in the French national health insurance database. Patients were followed from 1 January 2009 to 31 December 2018. The risks of biliary tract cancer and liver transplantation associated with thiopurines and anti-TNF exposure were assessed with marginal structural Cox proportional hazard models, adjusting for baseline demographics and comorbidities, and time-varying medications and PSC activity. RESULTS: Among the 1929 patients with PSC and IBD included, 37 biliary tract cancers and 83 liver transplantations occurred. Compared with patients not exposed to thiopurines or anti-TNF agents, patients exposed to thiopurines (hazard ratio [HR], 1.05; 95% confidence interval [CI], 0.39-2.82) or anti-TNF agents (HR, 0.59; 95% CI, 0.13-2.80) had no excess risk of biliary tract cancer. Similarly, patients exposed to thiopurines (HR, 0.67; 95% CI, 0.30-1.48) or anti-TNF agents (HR, 0.68; CI, 0.22-2.09) had no excess risk of liver transplantation. CONCLUSIONS: Patients with PSC and IBD who are exposed to thiopurines or anti-TNF agents are not at excess risk of biliary tract cancer or liver transplantation.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Biron A, Beaugerie L, Chazouillères O, et al. Impact of thiopurines and tumour necrosis factor antagonists on primary sclerosing cholangitis outcomes in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2022. PMID: 35789494. doi:10.1111/apt.17123

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。